Market Closed -
OTC Markets
03:54:55 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
0.0137
USD
|
-31.50%
|
|
-31.50%
|
-88.91%
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
285.5
|
275.3
|
512.3
|
1,743
|
1,428
|
411.4
|
Enterprise Value (EV)
1 |
269.8
|
349.5
|
780.6
|
1,856
|
1,538
|
495.9
|
P/E ratio
|
29.2
x
|
-1.25
x
|
-1.44
x
|
-5.25
x
|
-3.2
x
|
-0.65
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1.88
x
|
13
x
|
16.3
x
|
43.6
x
|
27
x
|
6.55
x
|
EV / Revenue
|
1.78
x
|
16.5
x
|
24.8
x
|
46.4
x
|
29.1
x
|
7.89
x
|
EV / EBITDA
|
4.55
x
|
-2.89
x
|
-4.24
x
|
-9.74
x
|
-4.33
x
|
-1.36
x
|
EV / FCF
|
8.58
x
|
-2.17
x
|
-5.89
x
|
-14.6
x
|
-9.16
x
|
19.3
x
|
FCF Yield
|
11.6%
|
-46%
|
-17%
|
-6.83%
|
-10.9%
|
5.19%
|
Price to Book
|
1.43
x
|
1.31
x
|
6.89
x
|
11.1
x
|
18.1
x
|
-24.5
x
|
Nbr of stocks (in thousands)
|
75,125
|
114,707
|
151,566
|
255,370
|
306,996
|
464,312
|
Reference price
2 |
3.800
|
2.400
|
3.380
|
6.825
|
4.650
|
0.8860
|
Announcement Date
|
3/16/18
|
3/15/19
|
3/3/20
|
2/19/21
|
3/11/22
|
3/16/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
151.9
|
21.19
|
31.43
|
39.99
|
52.9
|
62.84
|
EBITDA
1 |
59.25
|
-120.8
|
-184.2
|
-190.5
|
-355.6
|
-365.3
|
EBIT
1 |
52.17
|
-129.5
|
-195.2
|
-201.5
|
-368
|
-378.5
|
Operating Margin
|
34.36%
|
-610.94%
|
-620.97%
|
-503.99%
|
-695.68%
|
-602.33%
|
Earnings before Tax (EBT)
1 |
-24.93
|
-218.8
|
-363.5
|
-316.4
|
-462.7
|
-580.2
|
Net income
1 |
9.132
|
-203.5
|
-292.1
|
-298.5
|
-428.3
|
-572.8
|
Net margin
|
6.01%
|
-960.41%
|
-929.21%
|
-746.41%
|
-809.63%
|
-911.6%
|
EPS
2 |
0.1300
|
-1.920
|
-2.354
|
-1.300
|
-1.453
|
-1.370
|
Free Cash Flow
1 |
31.43
|
-160.9
|
-132.5
|
-126.7
|
-168
|
25.73
|
FCF margin
|
20.7%
|
-759.08%
|
-421.45%
|
-316.97%
|
-317.52%
|
40.95%
|
FCF Conversion (EBITDA)
|
53.05%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
344.19%
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/16/18
|
3/15/19
|
3/3/20
|
2/19/21
|
3/11/22
|
3/16/23
|
Fiscal Period: December |
2021 Q1
|
2021 Q2
|
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
---|
Net sales
1 |
14.26
|
13.51
|
12.06
|
13.08
|
18.38
|
11.46
|
17.4
|
15.59
|
16.25
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-84.9
|
-100.6
|
-90.26
|
-114
|
-106.9
|
-118.4
|
-109.4
|
-169.6
|
-
|
Operating Margin
|
-595.62%
|
-744.21%
|
-748.32%
|
-871.9%
|
-581.36%
|
-1,032.73%
|
-628.98%
|
-1,087.77%
|
-
|
Earnings before Tax (EBT)
|
2.631
|
-167.3
|
-119.8
|
-178.1
|
-38.95
|
-220.6
|
-91.7
|
-210.5
|
-
|
Net income
|
2.51
|
-166.6
|
-119.8
|
-144.4
|
-40.82
|
-218.8
|
-89.58
|
-223.7
|
-
|
Net margin
|
17.61%
|
-1,233.18%
|
-993.23%
|
-1,104.44%
|
-222%
|
-1,908.73%
|
-514.8%
|
-1,434.47%
|
-
|
EPS
2 |
0.0100
|
-0.5700
|
-0.4000
|
-0.4700
|
-0.1200
|
-0.5400
|
-0.2000
|
-0.4900
|
-0.2600
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
5/5/21
|
8/6/21
|
11/5/21
|
3/11/22
|
5/5/22
|
8/15/22
|
11/8/22
|
3/16/23
|
5/15/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
-
|
74.3
|
268
|
113
|
111
|
84.5
|
Net Cash position
1 |
15.7
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-0.6147
x
|
-1.456
x
|
-0.5927
x
|
-0.3113
x
|
-0.2314
x
|
Free Cash Flow
1 |
31.4
|
-161
|
-132
|
-127
|
-168
|
25.7
|
ROE (net income / shareholders' equity)
|
7.58%
|
-103%
|
-302%
|
-362%
|
-392%
|
-2,047%
|
ROA (Net income/ Total Assets)
|
7.83%
|
-15.3%
|
-20.6%
|
-23%
|
-37.4%
|
-40.5%
|
Assets
1 |
116.7
|
1,328
|
1,415
|
1,296
|
1,146
|
1,414
|
Book Value Per Share
2 |
2.650
|
1.830
|
0.4900
|
0.6200
|
0.2600
|
-0.0400
|
Cash Flow per Share
2 |
0.2700
|
1.380
|
0.1400
|
0.2100
|
0.1200
|
0.0500
|
Capex
1 |
11
|
21.2
|
11.4
|
6.53
|
8.87
|
13.7
|
Capex / Sales
|
7.23%
|
100.01%
|
36.4%
|
16.33%
|
16.77%
|
21.73%
|
Announcement Date
|
3/16/18
|
3/15/19
|
3/3/20
|
2/19/21
|
3/11/22
|
3/16/23
|
|
1st Jan change
|
Capi.
|
---|
| -88.91% | 7.45M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.74B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|